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Abstract: Neuroblastoma is a childhood solid tumour originating from undifferentiated neural
progenitor cells of the sympathetic nervous system. Drug resistance of childhood cancer neuroblastoma
is a serious clinical problem. In the present study, we aimed to identify novel drugs that can inhibit
the growth and survival of chemoresistant neuroblastoma. High-throughput screening identified a
small molecule, epi-enprioline that was able to induce apoptosis of vincristine-resistant neuroblastoma
cells via the mitochondrial apoptotic pathway. Epi-enprioline reduced tumour growth in multiple
preclinical models, including an orthotopic neuroblastoma patient-derived xenograft model in vivo.
In summary, our data suggest that epi-enprioline can be considered as a lead compound for the
treatment of vincristine-resistant neuroblastoma uncovering a novel strategy, which can be further
explored as a treatment for drug-resistant neuroblastoma.
Keywords: chemoresistance; neuroblastoma; epi-enprioline; apoptosis; vincristine
1. Introduction
Treatment strategies for neuroblastoma (NB) patients include chemotherapy, including
cyclophosphamide, cisplatin, doxorubicin, etoposide, carboplatin, and vincristine, either in combination
or alone followed by surgical resection, myeloablation, and autologous stem cell rescue, radiation,
and immunotherapy [1,2]. Recurrence in high-risk patients is observed in more than 50% of children
with high-risk disease [3]. Since options for tackling chemoresistant NB in clinical practice are limited,
there is an urgent need for developing additional treatment strategies.
Treatment failure due to multi-drug resistance against chemotherapeutic agents is seen for
over 90% of metastatic cancer patients [4,5]. Resistance to a given drug can be either pre-existing
(intrinsic resistance) [6] or occur during the course of treatment (acquired resistance) [7]. There are
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numerous mechanisms involved in the development of multiple drug resistance [7,8]. These can be
summarised as increased removal of drugs by transporters, enhanced drug metabolism, reduced cellular
uptake, changes in the expression of drug targets, intracellular drug sequestration, and changes in
the expression of genes involved in cell death, cell cycle, or DNA repair. Other processes that have
been linked to drug resistance include mitochondrial alteration, autophagy, epithelial-mesenchymal
transition, and cancer cell stemness. Among these mechanisms, increased expression of efflux pumps,
which leads to decreased intracellular drug concentrations, is the most studied [9,10].
Drug resistance due to alteration in cell cycle checkpoints is mostly seen in combination
therapies [11]. Reduced intracellular activation of pro-drugs and drug detoxification by the cytochrome
P450 enzymes and glutathione S-transferases, respectively, are other well-studied mechanisms
of chemoresistance [12,13]. The altered expression of pro-apoptotic proteins (BAX and BAK) or
anti-apoptotic proteins (BCL2, BCL-XL and MCL1) can directly affect drug resistance of cancer
cells [14,15]. The epithelial-mesenchymal transition process characterised by a dissociation of cell–cell
contacts and alteration of the cytoskeletal network was recently shown to mediate drug resistance in
different types of cancer cells [16,17].
In the present study, we have used previously established vincristine-resistant NB cell lines
to screen for novel drugs against treatment-resistant NB. Our high-throughput screening identified
epi-enprioline, which could limit the growth of vincristine-resistant NB by inducing cell death via the
intrinsic mitochondrial pathway of apoptosis.
2. Results
To identify a new anti-cancer drug that can affect the survival of vincristine-resistant neuroblastoma
(NB) cells (VCR-20), we performed cell survival screening assay by using 10 µM of each 1360 small
molecules from the National Cancer Institute (NCI). Eleven molecules could reduce the survival of
resistant cells by 50% or more (Figure 1A,B). These identified small molecules were subsequently tested
in a concentration-dependent cell survival assay. While no differences in cell survival could be detected
when cells were grown at 0.01 µM of the small molecules, a significant difference could be observed
after treatment with 0.1 µM of the racemic epi-enprioline (Figure 1C). To gain insight into the structural
features of epi-enpiroline, a single crystal X-ray diffraction (scXRD) structure was solved and compared
to the known structure of enpiroline (Figure 1D and Figure S1). The electrostatic potential surface map
of epi-enpiroline was also calculated to probe the binding motif of this structure (Figure 1E).
Treatment of vincristine-resistant NB cells with epi-enprioline reduces both proliferation
and number of surviving cells (Figure 2A,B), as well as the number of colonies (Figure 2C).
The sensitivity of other vincristine-resistant NB cells to epi-enprioline was confirmed using
SK-N-AS-VCR-20 (IC50 = 1.2 ± 0.7 µM) and UKF-NB-4-VCR-50 (IC50 = 3.05 ± 0.7 µM). Treatment of
these chemoresistant NB cells with epi-enprioline reduced proliferation and cell survival (Figure 2D–G).
Furthermore, LU-NB-2 PDX cells, derived from a NB brain metastasis following treatment relapse were
highly sensitive for epi-enprioline with an IC50 value of 0.5µM (Figure 2H). Treatment with epi-enprioline
caused markedly decreased LU-NB-2 PDX cell viability (Figure 2I). In addition, epi-enprioline was not
affecting the survival of primary embryonic fibroblasts (Figure S2).
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Figure 1. Identification of epi-enprioline as a selective inhibitor of neuroblastoma Be2c cells. (A) Be2c-
VCR cells (VCR-20) were treated with small molecules or DMSO for 48 h. Cell viability was measured 
using the MTT assay and calculated as fold changes compared to DMSO-treated cells (n = two 
independent experiments in triplicate). (B) The chemical structure of molecules that could reduce the 
survival of resistant cells by at least 50%. (C) VCR-20cells were treated with different concentrations 
of molecules identified in Figure 1A. Cell viability was measured using MTT assay and calculated as 
fold changes compared to DMSO-treated cells (n = two independent experiments in triplicate, mean 
± SEM). (D) Chemical structures of epi-enpiroline and enpiroline. Arrows highlight the piperidine 
nitrogen atom in each structure. (E) Electrostatic potential surface map of epi-enpiroline in a low-
energy conformation. 
Treatment of vincristine-resistant NB cells with epi-enprioline reduces both proliferation and 
number of surviving cells (Figure 2A,B), as well as the number of colonies (Figure 2C). The sensitivity 
of other vincristine-resistant NB cells to epi-enprioline was confirmed using SK-N-AS-VCR-20 (IC50 = 
1.2 + 0.7 µM) and UKF-NB-4-VCR-50 (IC50 = 3.05 + 0.7 µM). Treatment of these chemoresistant NB 
cells with epi-enprioline reduced proliferation and cell survival (Figure 2D–G). Furthermore, LU-NB-
2 PDX cells, derived from a NB brain metastasis following treatment relapse were highly sensitive 
for epi-enprioline with an IC50 value of 0.5 µM (Figure 2H). Treatment with epi-enprioline caused 
markedly decreased LU-NB-2 PDX cell viability (Figure 2I). In addition, epi-enprioline was not 
affecting the survival of primary embryonic fibroblasts (Figure S2). 
Figure 1. Identification of epi-enprioline as a selective inhibitor of neuroblastoma Be2c cells. (A) Be2c-VCR cells (VCR-20) were treated with small molecules or
DMSO for 48 h. Cell viability was measured using the MTT assay and calculated as fold changes compared to DMSO-treated cells (n = two independent experiments
in triplicate). (B) The chemical structure of molecules that could reduce the survival of resistant cells by at least 50%. (C) VCR-20cells were treated with different
concentrations of molecules identified in Figure 1A. Cell viability was measured usi g MTT assay an calculated as fold chang s compared to DMSO-treated cells (n =
two independent experiments in triplicate, mean ± SEM). (D) Chemical structures of epi-enpiroline and enpiroline. Arrows highlight the piperidine nitrogen atom in
each structure. (E) Electrostatic potential surface map of epi-enpiroline in a low-energy conformation.
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Figure 2. Epi-enprioline mediates reduced proliferation and cell survival. (A) VCR-20 cells were 
treated with 0.5 µM epi-enprioline and cell proliferation was evaluated at different time points during 
the course of 72 h. (mean ± SEM; n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control cells 
(ANOVA, Tukey’s test). (B) VCR-20 cells were treated with 0.5 µM epi-enprioline and stained with PI 
for detecting dead cells (mean ± SEM; n = 3). (C) VCR-20 cells were treated with the indicated 
concentrations of epi-enprioline for 15 d for clonogenic determinations. Representative well and 
quantitative data are shown (mean ± SEM; n = 3). n.s. = non-significant, *** p < 0.001 compared to 
control cells (ANOVA, Tukey’s test). (D) SK-N-AS-VCR-20 cells were treated with 1.2 µM epi-
enprioline for a crystal violet proliferation assay at different time-points during the course of 72 h. 
(Mean ± SEM; n = 3). (E) SK-N-AS-VCR-20 cells were treated with 1.2 µM epi-enprioline and stained 
with PI for detecting dead cells (mean ± SEM; n = 3). (F) UKF-NB-4-VCR-50 were treated with 3 µM 
epi-enprioline and cell proliferation was evaluated at different time-points during the course of 72 h. 
(Mean ± SEM; n = 3). (G) UKF-NB-4-VCR-50 cells were treated with 3 µM epi-enprioline and stained 
with PI for detecting dead cells (mean ± SEM; n = 3). (H) LU-NB-2 patient-derived xenograft (PDX) 
cells were treated with epi-enprioline and percentage of surviving tumor cells at different 
concentrations is shown. (n = 3). (I) Cell viability of treated LU-NB-2 PDX cells was assessed at 
different time-points using the CellTiter-Glo cell viability assay. (mean ± SEM; n = 3). VC = vincristine; 
epi = epi-enprioline. 
The early effect of epi-enprioline (after 24 h) on cell death and cell cycle was demonstrated for 
VCR-20 cells, where the frequency of cells in subG1 was higher in 0.5 µM epi-enprioline-treated 
compared to control cells (Figure 3A). This effect was even more pronounced after treatment with 1.0 
µM of epi-enprioline (Figure 3A). Flow cytometry analysis showed epi-enprioline dose-dependent cell 
shrinkage characterised by a decrease of cell size and gain of granularity (Figure 3B), which is a 
hallmark of cells undergoing apoptosis [18]. Annexin V and PI co-staining followed by flow 
cytometry analysis also demonstrated epi-enprioline-induced apoptosis (Figure 3C). Changes in 
Figure 2. Epi-enprioline mediates reduced proliferation a d cell survival. (A) VCR-20 cells w re treat d
with 0.5 µM epi-enprioline and c ll proliferation was ev luated t ifferent time points during the
course of 72 h. (mean ± SEM; n = 3). * p < 0. 5, ** p < 0.01, *** . co pared to control cells
(ANOVA, Tukey’s test). ( ce ls were treated with 0.5 µM epi-enpr oline and stained with
PI for detecting dead cells (mean ± SEM; n = 3). (C) VCR-20 cells were treated with the indicated
concentrations of epi-enprioline for 15 d for clonogenic deter Representative well and
quanti ative data are shown (mean ± SE ; n = 3). on-significant, * p < 0. 01 compared to
control cells (ANOVA, Tukey’s test). (D) SK-N-AS-VCR-20 cells w re treat d with 1.2 µM epi-enpriol ne
for a crystal violet proliferation assay at different time-points during the course of 72 h. (Mean ± SEM;
n = 3). (E) SK-N-AS-VCR-20 cells were treated ith 1.2 µM epi-enprioline a d stai d with PI for
detecting dea c lls (mean ± SEM; n = 3). (F) UKF-NB-4-VCR-50 were treated ith 3 µM epi-enprioline
and cell proliferation was evaluated at different time-points during the course of 72 h. (Mean ± SEM;
n = 3). (G) UKF-NB-4-VCR-50 cells were treated ith 3 µM epi-enprioline a d stai ed with PI for
detecting dead cells (mean ± SEM; n = 3). (H) LU-NB-2 patient-derived xenograft (PDX) cells were
treated ith epi-enprioline and percentage of surviving tumor cells at different concentrations is shown.
(n = 3). (I) Cell viability of treated LU-NB-2 PDX cells was assessed at different time-points using the
CellTiter-Glo cell viability assay. (mean ± SEM; n = 3). VC = vincristine; epi = epi-enprioline.
The early effect of epi-enprioline (after 24 h) on cell death and cell cycle was demonstrated
for VCR-20 cells, where the frequency of cells in subG1 was higher in 0.5 µM epi-enprioline-treated
compared to control cells (Figure 3A). This effect was even more pronounced after treatment with 1.0µM
of epi-enprioline (Figure 3A). Flow cytometry analysis showed epi-enprioline dose-dependent cell
shrinkage characterised by a decrease of cell size and gain of granularity (Figure 3B), which is a hallmark
of cells undergoing apoptosis [18]. Annexin V and PI co-staining followed by flow cytometry analysis
also demonstrated epi-enprioline-induced apoptosis (Figure 3C). Changes in intracellular calcium are
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associated with apoptosis via mitochondrial membrane disruption [19]. We used the calcium-sensitive
fluorescence probe Fluo-3/AM to monitor changes in intracellular calcium levels. The fluorescence
emitted from epi-enprioline-treated cells was shifted to a higher intensity compared to control cells,
indicating an increase in the intracellular calcium concentration (Figure 3D). Furthermore, we used the
potential-independent mitochondria-specific vital dye MitoTracker Green to measure the accumulation
of depolarised mitochondria [20]. MitoTracker Green is a lipophilic thiol-reactive dye that selectively
labels the mitochondrial inner membrane and matrix for measuring of cellular mitochondrial content.
The increase of MitoTracker Green fluorescence is a sign of mitochondrial depolarisation due to a loss
of mitochondria potential. Analysis by flow cytometry revealed a threefold and sevenfold increase in
MitoTracker Green staining of cells treated with 0.5 and 1.0 µM epi-enprioline, respectively (Figure 3E).
Further, DiOC6 staining followed by flow cytometry analysis confirmed the loss of mitochondrial
membrane potential (∆Ψm) in epi-enprioline-treated compared to control cells (Figure 3F). Activation of
caspase 3 in epi-enprioline-treated cells demonstrated the execution-phase of cell apoptosis (Figure 3G).
These results suggest that epi-enprioline interferes with the intrinsic mitochondria-dependent apoptosis
pathway in vincristine-resistant NB cells.
Next, we subcutaneously implanted VCR-20 cells in nude mice. Caliper measured visible tumours
were treated with epi-enprioline or DMSO control. This treatment resulted in reduced volume of
epi-enprioline-treated tumours compared to control mice (Figure 4A). This proof-of-concept experiment
suggest that epi-enprioline has potential as lead candidate. As expected, an elevated number of cleaved
caspase 3 immunoreactive cells was observed in tumour cells isolated from epi-enprioline-treated
mice compared to control animals (Figure 4B). In another set of experiments, VCR-20 was injected
orthotopically into the adrenal gland of mice before intraperitoneal (i.p.) treatment with epi-enprioline.
In vivo imaging using IVIS-CT scan demonstrated that epi-enprioline-treated mice show reduced
tumor growth compared to control mice (Figure 4C,D) and prevented tumor metastasis to distant
organs (Figure 4E) without any significant changes in the weight of the animals (Figure S3A).
Finally, LU-NB-2 PDX cells were injected orthotopically into the adrenal gland and mice were
treated i.p. with epi-enprioline. Treated mice showed decreased tumor growth as compared to
controls (Figure 4F,G), without any significant changes in the weight of the animals (Figure S3B).
Importantly, tumor metastasis to distant organs could only be observed in control mice (Figure 4H;
Videos S1,2).
To examine whether epi-enprioline can change the levels of vincristine resistance-associated genes,
we performed expression profiling of resistance-associated genes following epi-enprioline treatment.
By analysing gene expression data we set the cutoff for the fold change at +/−2.0 and evaluated the
following contrasts: (i) VCR-10 vs. parental (26 genes); (ii) VCR-10-enprioline vs. parental (29 genes);
and (iii) VCR-10-enprioline vs. VCR-10 (five genes). Differentially expressed gene lists were then
compared to identify commonly and uniquely regulated genes (Figure 5). VCR-10 vs. parental contrast
showed only five unique genes (all upregulated). Among the eight unique genes in VCR-10-enprioline
vs. parental, we found members of ABC-transporters and cytochrome enzymes. Of note, CYP1A1
was the unique downregulated gene in all three of the contrasts we compared. We next performed
GO and KEGG Pathway Enrichment Analysis with gene lists from the above contrasts. Figure S4
reports the top ten of enriched GO terms and pathways (full results in Table S1). In VCR-10 vs.
parental and VCR-10-enprioline vs. parental, pathways in cancer was the most enriched KEGG
pathway; in addition, several cancer types were found enriched in KEGG pathway analysis (Figure S4).
GO molecular functions were overrepresented in terms related to protein kinase activities (Figure
S4). Among the biological processes, we found a higher presence of apoptosis and cell death related
GO terms in VCR-10-enprioline vs. parental contrast compared to VCR-10 vs. parental. By using the
VCR-10-enprioline vs. VCR-10 list (five genes), we found the enrichment of xenobiotics and drug
metabolic processes (GO molecular function) and chemical carcinogenesis (KEGG).
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Figure 3. Epi-enprioline mediates cell death via the mitochondrial apoptotic pathway. (A) Cells were
treated with epi-enprioline and stained with Hoechst 33342 for the quantification of the subG1 apoptotic
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population. Representative plots and quantitative data are reported (mean ± SEM; n = 3). *** p < 0.001
compared to control cells (ANOVA, Tukey’s test). (B) VCR-20 cells were seeded and treated with
epi-enprioline. After 24 h, cells were collected and acquired by flow cytometry. Representative plots are
reported with the respective gate (n = 3). (C) Cells administered with epi-enprioline for 24 h were stained
for the phosphatidylserine exposure with FITC-conjugated annexin V and the vital dye PI. *** p < 0.001
compared to control cells (ANOVA, Tukey’s test, n = 4). (D) Cells were treated with epi-enprioline
(labelled in green, orange and red, respectively) and after 24 h, stained with the calcium dye Fluo-3 for
quantification of the cytosolic Ca2+ concentration by flow cytometry(mean ± SEM; n = 3). *** p < 0.001
compared to control cells (ANOVA, Tukey’s test). (E) Cells were treated with epi-enprioline (labelled in
green, orange and red, respectively) and after 24 h, stained with the MitoTracker Green (MTG) dye
for the quantification of mitochondrial inner membrane and matrix(mean ± SEM; n = 3). *** p < 0.001
compared to control cells (ANOVA, Tukey’s test). (F) Cells administered with epi-enprioline for 24 h
were co-stained with the vital dye PI and the mitochondrial membrane potential (∆ψm)-sensing dye
DiOC6. White columns illustrate early apoptosis (PI−DiOC6 low) while grey columns illustrate late
apoptosis (PI+DiOC6 low). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control cells (ANOVA,
Tukey’s test). (G) Cells were treated with epi-enprioline (labelled in green, orange and red, respectively)
and after 24 h labeled with the FITC-conjugated cleaved caspase-3 (mean ± SEM; n = 3).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 16 
 
 
Figure 4. Epi-enprioline reduces tumour growth in vivo. (A) Nude mice were injected with 2 × 106 
VCR-20 cells. When the mice developed visible subcutaneous tumours using caliper (100–125 mm3), 
they were treated intra-tumour, 2–3 cm away from the tumour, with 10 mg/kg of epi-enprioline or 
DMSO control (n = 6 mice in each group). The mean tumor volume for each treatment group was 
graphed plus/minus standard errors (* p < 0.05). (B) Immunohistochemistry analysis of tumour 
biopsies isolated from control (Ctrl) or epi-enprioline-treated VCR-20 cells using haemotoxylin and 
eosin or antibodies against cleaved caspase-3. Arrowheads indicate cleaved caspase-3 positive cells 
(left panel). Quantification of the number of cleaved caspase-3 (Asp175) positive cells in the sections 
isolated from control and epi-enprioline-treated group (Right panel, mean ± SEM, ** p < 0.01, n = 3). 
(C) Nude mice were subjected to orthotopic implantation into adrenal gland with VCR-20-GFP-Luc 
cells (1 × 106) and a week later, the tumor growth was monitored by non-invasive 2D bioluminescence 
(BLI) imaging using IVIS-CT spectrum. Mice (n = 6) showing tumor growth signals were randomized 
into DMSO and epi-enprioline treatment groups. BLI signal intensity was quantified in Total flux 
(Photons/s) after deducting the average background signal (Bkg) from measurement region of interest 
(ROI) using the Living image analysis software (mean ± SEM, ** p < 0.01). (D) Representative images 
of tumor growth (VCR-20 GFP-Luc cells) in mice treated with DMSO or epi-enprioline, † indicates 
animal not surviving the entire study period. (E) Ventral side 3D µCT representative images were 
taken to show distant metastasis of VCR-20 Luc cells in control animals after orthotopic implantation 
into adrenal gland. Site of implantation is shown by yellow arrowhead. The mouse organ atlas (ii and 
iii) was overlaid on the 3D skeletal image (i) to show the possible metastatic anatomical sites (white 
arrowheads) using Living image analysis software. (F) Nude mice were subjected to orthotopic 
implantation into adrenal gland with LU-NB-2 GFP-Luc (2 × 106). One week later, the tumor growth 
was monitored by non-invasive 2D bioluminescence (BLI) imaging, using IVIS-CT spectrum. Mice (n 
= 6) showing tumor growth signals were randomized into DMSO or epi-enprioline treatment groups. 
BLI signal intensity was quantified in Total flux (Photons/s) after deducting the average background 
signal (Bkg) from measurement region of interest (ROI) using the Living image analysis software 
Figure 4. Epi-enprioline reduces tumour growth in vivo. (A) Nude mice were injected with 2 × 106
VCR-20 cells. When the mice developed visible subcutaneous tumours using caliper (100–125 mm3),
they were treated intra-tumour, 2–3 cm away from the tumour, with 10 mg/kg of epi-enprioline or
DMSO control (n = 6 mice in each group). The mean tumor volume for each treatment group was
graphed plus/minus standard errors (* p < 0.05). (B) Immunohistochemistry analysis of tumour biopsies
isolated from control (Ctrl) or epi-enprioline-treated VCR-20 cells using haemotoxylin and eosin or
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antibodies against cleaved caspase-3. Arrowheads indicate cleaved caspase-3 positive cells (left panel).
Quantification of the number of cleaved caspase-3 (Asp175) positive cells in the sections isolated from
control and epi-enprioline-treated group (Right panel, mean ± SEM, ** p < 0.01, n = 3). (C) Nude mice
were subjected to orthotopic implantation into adrenal gland with VCR-20-GFP-Luc cells (1 × 106) and
a week later, the tumor growth was monitored by non-invasive 2D bioluminescence (BLI) imaging
using IVIS-CT spectrum. Mice (n = 6) showing tumor growth signals were randomized into DMSO
and epi-enprioline treatment groups. BLI signal intensity was quantified in Total flux (Photons/s) after
deducting the average background signal (Bkg) from measurement region of interest (ROI) using
the Living image analysis software (mean ± SEM, ** p < 0.01). (D) Representative images of tumor
growth (VCR-20 GFP-Luc cells) in mice treated with DMSO or epi-enprioline, † indicates animal not
surviving the entire study period. (E) Ventral side 3D µCT representative images were taken to show
distant metastasis of VCR-20 Luc cells in control animals after orthotopic implantation into adrenal
gland. Site of implantation is shown by yellow arrowhead. The mouse organ atlas (ii and iii) was
overlaid on the 3D skeletal image (i) to show the possible metastatic anatomical sites (white arrowheads)
using Living image analysis software. (F) Nude mice were subjected to orthotopic implantation into
adrenal gland with LU-NB-2 GFP-Luc (2 × 106). One week later, the tumor growth was monitored
by non-invasive 2D bioluminescence (BLI) imaging, using IVIS-CT spectrum. Mice (n = 6) showing
tumor growth signals were randomized into DMSO or epi-enprioline treatment groups. BLI signal
intensity was quantified in Total flux (Photons/s) after deducting the average background signal (Bkg)
from measurement region of interest (ROI) using the Living image analysis software (mean ± SEM,
** p < 0.01). (G) Representative images of tumor growth (LU-NB-2 GFP-Luc) in mice treated with DMSO
or epi-enprioline, † indicates animal not surviving the entire study period. (H) Ventral side 3D µCT
representative images were taken to show distant metastasis of LU-NB-2 GFP-Luc cells after orthotopic
implanted into adrenal gland. Site of implantation is shown by yellow arrowhead. The mouse organ
atlas (ii and iii) was overlaid on the 3D skeletal image (i) to show the possible metastatic anatomical
sites (white arrowheads) using Living image analysis software.
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Figure 5. Identification of genes involved in drug resistance in epi-enprioline-treated and non-treated
VCR-10 cells. The Human Cancer Drug Resistance RT2 Profiler PCR Array revealed up- and
downregulated genes involved in drug resistance in epi-enprioline-treated and non-treated VCR-10
cells. The levels of relative expression of each gene in the two samples are plotted against each other in
a Venn-diagram after normalisation was done using the housekeeping genes. The line in the middle
indicates relative fold changes. The left and right lines indicate the fold change in gene expression
threshold, which was defined as 1.5-fold.
3. Discussion
Cure of children with high-risk NB disease is limited despite aggressive multimodal treatment
strategies including surgery, radiotherapy, stem cell transplantation and chemotherapy. Simila to other
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cancer diseases, the acquisition of drug resistance by tumour cells is of great importance to developing
novel drugs [3]. As MYCN amplification is indeed associated with poor prognosis in NB, we decided
to use previously generated VCR cells, which is a MYCN amplified aggressive and metastasis cell
line originating from NB patient. In addition to p53 mutations, these cells harbor other important
pathogenic genomic aberrations such as 1p21.1–36.3 deletion and 9p21–24.3 as well as 3p22.1–25.3 loss.
Vincristine is a vinca alkaloid that blocks cell growth by interfering with mitosis. Vincristine is included
in the rapid COJEC (Cisplatin (C), vincristine (O), carboplatin (J), etoposide (E), and cyclophosphamide
(C)) treatment regimen. In the present study, we investigated the influence of vincristine resistance on
cell growth and to identify a novel inhibitor that can limit the growth of these cells.
Searching for an alternative anti-cancer drug that can affect the survival of VCR NB cells,
we screened a library of 1360 small molecules. The screening identified 11 compounds with significant
activity and among them, racemic epi-enprioline showed the highest cytotoxic effect. Structurally,
epi-enpiroline is a diasteromer of enpiroline, a compound that was originally developed as an
anti-malarial drug agent against multidrug resistance cases. Interestingly, both enantiomers of
enpiroline exhibit antimalarial activity as they share binding motif with the natural products quinine
and quinidine respectively [21,22]. The solid-state structure of epi-enpiroline was found to closely
resemble that of enprioline with respect to conformation but the different stereochemistry of the two
compounds reflects in a quite different binding motif.
Since treatment of VCR NB cells with epi-enprioline resulted in growth retardation and reduced
colony growth, we analysed the mechanism of cell survival. Increase of the subG1 fraction of
the cell cycle, cell shrinkage, phosphatidylserine outer membrane translocation, as well as loss of
mitochondrial membrane integrity, provided evidence of a pro-apoptotic function of epi-enprioline.
Generally, apoptosis is divided into the extrinsic and intrinsic pathways. While the extrinsic
pathway is mediated via cell surface death receptors, the intrinsic pathway is mediated through
the mitochondria [23–25]. Applying different strategies, including measuring changes in intracellular
calcium concentration (which is associated with apoptosis via mitochondrial membrane disruption),
labelling of the mitochondrial inner membrane for measuring cellular mitochondrial content with
MitoTracker and the measurement of the mitochondrial membrane potential (∆Ψm) using the DiOC6(3)
dye, provided evidence that epi-enprioline interferes with the intrinsic mitochondria-dependent
apoptotic pathway.
Gene expression profiling identified multiple genes up- or downregulated in epi-enprioline-treated
VCR-10 cells in comparison to either parental or untreated VCR-10 cells. Overall, we observed
downregulation of various genes in epi-enprioline-treated cells, including ABC-transporters such as
ABCB1 and ABCG2, which are known to be involved in drug resistance because of their role in the
efflux mechanisms. Moreover, the cytochrome C P450 enzymes associated with drug metabolism,
including CYP1A1, CYP3A4, CYP1A2, CYP2B6, CYP2C19, CYP2C8, anti-apoptotic gene BCL2, and other
genes involved in cell cycle progression, such as CDK2, CDK2D, and GSK3A, were also downregulated
in epi-enprioline treated Be2c-VCR cells. On the other hand, a number of genes such as AHR, ESR1,
CYP2E1, CYP2C9 and NAT2 were shown to be upregulated in epi-enprioline-treated VCR-10 cells.
GO enrichment analysis supported the findings reported above. Differentially expressed genes in
epi-enprioline-treated VCR-10 cells resulted in terms related to apoptosis and response to xenobiotics
among biological processes and protein kinases and drug binding molecular functions. Consistent
with the regulation of several cytochrome C P450 enzymes in VCR-10-enprioline, we found the
enrichment of the biological process; intrinsic apoptotic signalling pathway in response to DNA
damage. Several cancer types were enriched among the KEGG pathways. A direct comparison
between VCR-10-enprioline and VCR-10 showed the overrepresentation of GO categories involved in
drug and xenobiotic metabolic process and response to xenobiotic stimulus.
To establish the anti-cancer effect and toxicity of epi-enprioline in vivo, we applied a xenograft
transplantation experiment in athymic nude mice. Epi-enprioline treatment of mice bearing xenografts
of the vincristine-resistant cell line resulted in significant decrease in relative tumour volume compared
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to mice treated with vehicle control. Furthermore, orthotopic transplantation of vincristine-resistant or
PDX derived NB into the adrenal gland before treatment with epi-enprioline reduced tumor growth
and tumor metastasis. These data suggest that epi-enprioline can be considered as a lead compound
for a novel class of anti-cancer agents for the treatment of vincristine-resistant NB. Further studies
need to establish whether the anti-cancer function of epi-enprioline is restricted to NB or whether it
also applies to other chemo reagents and chemoresistant human cancer cells, in addition to future drug
toxicology studies. To summarize, we identified a small molecule, epi-enprioline, that exerted cytotoxic
effects against vincristine -resistant NB in vitro and in vivo.
4. Materials and Methods
4.1. Cell Culture
The human NB cell line SK-N-BE(2)-C (ATCC, CRL-2268, parental) was cultured at 37 ◦C
and 5% CO2 in minimum essential medium (MEM, HyClone, Thermo Fisher Scientific, MA, USA)
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich Sweden AB, Stockholm, Sweden)
and 1% penicillin/streptomycin (GIBCO, MA, USA). To generate vincristine-resistant cells (Be2c-VCR),
SK-N-BE(2)-C cells were cultured for 7 months with gradually increased concentrations of vincristine
ranging from 1–10 ng/mL. The 10 ng/mL Be2c-VCR cells (VCR-10) were treated further with escalating
concentration of 20 ng/mL (VCR-20) of vincristine for another month.
The non-MYCN-amplified neuroblastoma cell line SK-N-AS was kindly provided by
Dr. Angelika Eggert (Universität Duisburg-Essen, Germany). The MYCN-amplified, TP53-mutant
(C175F) neuroblastoma cell line UKF-NB-4 was derived from bone marrow metastases of a patient
harboring a stage IV neuroblastoma [26,27]. The vincristine-resistant sub-lines were established by
continuous exposure to step-wise increasing drug concentrations as previously described [28] and
derived from the Resistant Cancer Cell Line (RCCL) collection (https://www.kent.ac.uk/stms/cmp/
RCCL/RCCLabout.html). UKF-NB-4 cells were adapted to growth in the presence of vincristine
50 ng/mL (UKF-NB-4-VCR-50), SK-N-AS to vincristine 20 ng/mL (SK-N-AS-VCR-20). Cells were grown
at 37 ◦C in Iscove’s modified Dulbecco’s medium supplemented with 10% heat-inactivated foetal calf
serum and containing 100 IU/mL of penicillin and 100µg/mL streptomycin. The vincristine-adapted
sub-lines were continuously cultivated in the presence of the indicated drug concentrations.
LU-NB-2 patient-derived xenograft (PDX)-cells were established and characterized as previously
described [29,30]. Briefly, PDX cells were derived from a NB brain metastasis following treatment
relapse. Tumor cells contained 1p del, MYCN amplification and 17q gain. PDX cells were cultured as
free-floating 3D-spheres in serum-free medium consisting of Dulbecco’s Modified Eagle’s Medium
(DMEM) and GlutaMAXTM F-12 (3:1 ratio) supplemented with 1% penicillin/streptomycin, 2% B27
w/o vitamin A, 40 ng/µL basic fibroblast growth factor and 20 ng/µL epidermal growth factor.
Mouse embryonic fibroblast (MEF) cells were cultured in DMEM that was supplemented with
4500 mg/L l-glucose, 4 mm/L l-glutamine, and sodium pyruvate (hyclone, Thermo Scientific, Waltham,
MA, USA), 20% fetal bovine serum (FBS), and 100 IU/mL penicillin and streptomycin mixture
(Life Technologies, Carlsbad, CA, USA).
4.2. Drug Screening
VCR-20 cells were seeded in 96-well plates with a density of 5000 cells/well. Twenty-four hours
later, cells were treated in triplicate with 10 µM of 1360 small molecules/well obtained from the National
Cancer Institute (NCI) or dimethyl sulfoxide (DMSO) for 48 h. Cell viability (mean absorbance from
three wells) was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
tetrazolium reduction (MTT) assay and calculated as a fold change compared to DMSO-treated cells.
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4.3. Animal Model
VCR-20 cells (2.0× 106 cells in 0.1 mL phosphate buffered saline (PBS)) were subcutaneously injected
into the right flank of 4-week-old female NMR1-Foxb1 nude mice (Janvier Labs, Le Genest-Saint-Isle,
France). Mice were randomly assigned into two weight-matched groups with 6 mice in each group
receiving either epi-enprioline or DMSO. When the mice developed visible subcutaneous tumours,
they were treated with epi-enprioline (10 mg/kg) every day for 12 days. Tumour growth was followed
by measuring the volume every second day. The subcutaneous tumours were harvested, weighed and
processed for further study. The experiment was terminated when the tumors reached a volume
of 600–700 mm3. The animals were maintained under specific pathogen-free (SPF) conditions.
All experimental procedures were approved by the Malmö and Lund Animal Ethics Committee with
the ethical number M129-15 (Approval Date: 19 August 2015).
4.4. Establishment of Orthotopic Tumor and In Vivo Bioluminescence Imaging
Six to eight-weeks-old athymic nude mice were subjected to orthotopic implantation into
adrenal gland with either VCR-20 GFP-Luc cells (1 × 106) or with LU-NB-2 GFP-Luc PDX cells
(2 × 106). One week later, the tumor growth was monitored by non-invasive 2D bioluminescence
(BLI) imaging, using IVIS-CT spectrum (PerkinElmer, MA, USA). Mice showing tumor growth
signals were randomized into two groups (DMSO and epi-enprioline) based on their average BLI
signal intensity recorded in a defined region of interest (ROI) with average total flux (photons/s)
value of 7 × 105 and 4 × 105 among VCR-20 and LU-NB-2 implanted mice respectively. DMSO or
epi-enprioline (10 mg/kg)-treatment was given intraperitoneally every three days up to the end points.
Tumor growth and metastasis development was monitored using bioluminescence 2D and 3D µCT
imaging. Briefly, mice anesthetized with 3% isoflurane gas injected intraperitoneally with 150 mg
D-Luciferin/kg of body weight in PBS prior to imaging. Acquisition of 2D images was performed
sequentially with a five-minute interval between different segments of exposures (emission: open filter,
f/stop: 1, binning: 8). BLI signal intensity was quantified in Total flux (Photons/s) after deducting
the average background signal (Bkg) from measurement region of interest (ROI) using the Living
image analysis software (PerkinElmer, MA, USA). Ventral side 3D µCT images were taken to show
distant metastasis other than the tumor growth within the implanting regions in the adrenal gland.
The mouse organ atlas was overlaid on the 3D skeletal images together with images of mouse body
slices including coronal, sagittal and transaxial view to show the possible metastatic anatomical sites
using Living image analysis software (PerkinElmer, MA, USA).
4.5. Immunohistochemistry Staining
Formalin-fixed, paraffin-embedded xenograft tumor sections (5 µm) were deparaffinized using
routine techniques, and placed in 200 mL of EnVisionTM target retrieval solution (pH 6.0; Dako,
Hamburg Germany) for 20 min at 100 ◦C. After cooling for 20 min, slides were quenched with 3% H2O2
for 5 min before incubating with a primary antibody against cleaved caspase 3 (Abcam, ab2302, 1:500,
Cambridge, Storbritannien) to detect apoptotic cells using a Dako Autostainer. Immunostaining was
visualized using the EnVisonTM+ kit (Agilent Dako, Santa Clara, CA, USA). In addition, slides were
also stained with hematoxylin and eosin.
4.6. RT2 Profiler PCR Array Analysis
Gene expression profiling related to human cancer drug resistance was performed using a 384-well
RT2 Profiler PCR Array (PAHS-004Z, QIAGEN AB, Sollentuna, Sweden). Following total RNA
extraction, cDNA was synthesised from Be2c-parental, VCR-10 and epi-enprioline (1 µM, 24 h)-treated
VCR-10 cells based on the manufacturer’s instructions. Eighty-four different genes involved in cancer
cell drug resistance were analysed based on SYBR Green real-time PCR using the QuantStudio™ 7 Flex
(Applied Biosystems, CA, USA). Normalisation was performed using the five different housekeeping
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genes included in the array and the fold change was calculated using the RT2 Profiler PCR Array Data
Analysis from Qiagen (http://www.qiagen.com/geneglobe).
4.7. Gene Ontology and Pathway Enrichment
Differentially expressed gene lists were used to perform Gene Ontology (GO) and Pathway
Enrichment Analysis by using the tool WebGestalt (www.webgestalt.org). We used the overrepresentation
enrichment analysis method to query the GO and the KEGG databases with the default options.
p-values were calculated with the hypergeometric test and statistical significance level was set at false
discovery rate (FDR) ≤ 0.05.
4.8. Proliferation and Viability Assay
Cells were seeded in 96-well plates with a 5000 cells/well density. After the treatment, 10 µL of
alamarBlue reagent (ThermoFisher, MA, USA) was added to each well, mixed and then incubated
for 4 h at 37 ◦C in a CO2 incubator. The absorbance of each sample was measured using a scanning
microplate spectrophotometer reader (Synergy 2, Biotek, Winooski, VT, USA) by absorbance detection
at 570 nm or fluorescence detection at excitation and emission wavelengths of 540–570 and 580–610 nm,
respectively. IC50 values for each treatment were calculated using the GraphPad software. For cristal
violet proliferation assay, cells were seeded in 96-well plates with a 5000 cells/well density. Twenty-four
hours later, cells were treated or not with 0.5 µM epi-enprioline or DMSO for up to 72 h. Cells were
washed once with PBS and fixed with 4% paraformaldehyde (PFA) for 15 min. The PFA was removed,
and cells were stained for 30 min at room temperature with an aqueous solution containing 0.1%
(w/v) crystal violet. Cells were washed three times with distilled water before the administration of
200 µL/well of 10% acetic acid and shaking with micropipettes. The absorbance of each sample was
measured using a scanning microplate spectrophotometer reader (Synergy 2, Biotek) by absorbance
detection at 595 nm.
4.9. Clonogenic Assays
To evaluate clonogenic survival, cells were seeded at different concentrations (from 100 to
2000 cells/well) in 6-well plates. Upon 24 h of adaptation time, cells were treated with different
concentrations of epi-enprioline for 7 days in standard culture conditions. Colonies were then fixed
with 4% PFA, stained with an aqueous solution of 1% (w/v) crystal violet and counted. Only colonies
made up of >30 cells were included in the quantification. To evaluate clonogenic potential, cells were
seeded at low concentrations (100 cells/well) in 6-well plates and cultured in standard conditions for
15 days. Colonies were then fixed with 4% PFA, stained with an aqueous solution of 1% (w/v) crystal
violet and counted. Colonies made of >30 cells were included in the quantification, and colony size
was evaluated using the ImageJ software.
4.10. Apoptosis and DNA Fragmentation Assay
For apoptosis analyses, cells were fixed in PFA on coverslips and stained with a Vindelöv solution
containing propidium iodide (PI). After washing, the coverslips were mounted onto glass slides
and cells were examined by fluorescence microscopy. Cells were scored for apoptosis based on
nuclear morphology. Apoptosis was further evaluated using NucleoCounter NC-3000 (Chemometec,
Allerod, Denmark) in conformity with the DNA fragmentation assay. Cells grown in 6-well plates
were harvested by trypsinisation and pooled with the cells floating in the medium. After a short
centrifugation, the supernatant was removed, and precipitated cells were washed once with PBS.
After a second centrifugation, cells were resuspended in a small volume of PBS and the single-cell
suspensions were added to 70% ethanol for fixation. The samples were vortexed and stored for 12–24 h
at −20 ◦C. The ethanol-suspended cells were centrifuged and the ethanol carefully decanted. Cells
were washed once with PBS and then resuspended in NucleoCounter Solution 3 (1 µg/mL DAPI, 0.1%
Triton X-100 in PBS) followed by incubation for 5 min at 37 ◦C. Ten microliters of samples were loaded
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into a slide chamber (NC-slide A8) and the DNA fragmentation protocol was employed according to
the manufacturer’s instructions (Chemometec, Allerod, Denmark).
4.11. Cytofluorometric Studies
Cytofluorometric acquisitions were performed by means of a FACSVerse cytofluorometer
(BD Biosciences, CA, USA). Data were statistically evaluated using the Kaluza (Beckman Coulter,
Indianapolis, IN, USA) software. Only events characterised by normal forward scatter (FSC) and
side scatter (SSC) parameters were gated for inclusion in the statistical analysis after exclusion of
cell doublets.
1. Cell cycle analysis: For the quantification of cell cycle profiling (DNA content), live cells were
harvested, collected with the culture medium and resuspended in 0.3 mL pre-warmed growth
medium supplemented with 2 mM Hoechst 33342 (Sigma-Aldrich) for 30 min at 37 ◦C in a CO2
incubator. Cell suspensions were analysed on a cytometer with ultraviolet excitation and emission
collected at >450 nm. To quantify the apoptotic and DNA fragmented fraction, we measured the
subG1 population of cells.
2. Measurement of cell shrinkage: For the quantification of cell shrinkage, cells were harvested and
collected with the culture medium before FACS assessment without any staining. Cell size was
measured using the FSC and cell granularity using the SSC. Apoptotic cells are more granulated
and smaller than live cells.
3. Measurement of cell permeabilisatio: For the quantification of plasma membrane integrity,
cells were harvested and collected with the culture medium and stained with 0.5 to 1 µg/mL
7-aminoactinomycin (7AAD, which only incorporates into dead cells, from ThermoFisher) for
30 min at 37 ◦C before FACS assessment.
4. Measurement of cell scrambling and phosphatidylserine exposure: For the simultaneous
quantification of plasma membrane integrity and phosphatidylserine exposure, cells were
harvested and collected with the culture medium and stained with Annexin-V-FITC (1:200
dilution; ImmunoTools, Friesoythe, Germany) and 1 µg/mL PI (which only incorporates into
dead cells, from Sigma-Aldrich) for 30 min at 37 ◦C before FACS assessment.
5. Measurement of mitochondria accumulation: For staining mitochondria, cells were harvested and
collected with the culture medium and labelled for 45 min at 37 ◦C with 100 nM of MitoTracker
Green MTG (ThermoFisher, MA, USA) before FACS assessment. The signal shift is measured
comparatively to non-treated cells.
6. Measurement of intracellular calcium concentration: For the evaluation of cytosolic calcium,
cells were collected and suspended in growth medium supplemented with 5 µM of the calcium
tracker Fluo-3/AM (Biotium, Hayward, CA, USA). Cells were incubated at 37 ◦C for 30 min before
calcium-dependent fluorescence intensity measurement. The Fluo-3/AM is measured with an
excitation wavelength of 488 nm (blue laser) and an emission wavelength of 530 nm. The signal
shift and the geometric mean were measured comparatively to non-treated cells.
7. Measurement of cleaved caspase 3: To measure cleaved caspase 3, cells were fixed with 75%
(v/v) ethanol in PBS, permeabilized with 0.25% (v/v) Tween 20 in PBS and stained with a
FITC-conjugated Casp3 c (rabbit polyclonal #559341, BD-Bioscience).
4.12. Statistical Analyses
Statistical analyses were performed using the SigmaPlot or GraphPad Software. Results are
expressed as mean ± SEM or as a percent. p-values p < 0.05*, p < 0.01**, and p < 0.001*** were deemed
statistically significant. Statistical comparisons were assessed by analysis of variance (ANOVA) or by
the Student’s t-test.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/18/
6577/s1.
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